The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

Varda Space Industries achieved the first successful commercial space reentry in Australia, a milestone for the industry.

Varda Space Industries achieved the first successful commercial space reentry in Australia, a milestone for the industry.

Keytruda, which drove $25 billion in revenue in 2024. "Basically, what [Merck] showed in microgravity was they could take this cancer drug from something that would require a four- to six-hour ...

Patients in the study will receive a 1 mg dose of V940 via intramuscular (IM) injection or a matched placebo once every three weeks for up to nine doses, along with an infusion of Keytruda once ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for patients with stage 3 or 4 kidney cancer, who face high recurrence risk.

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

Keytruda, the biggest product in Merck’s ... In the hospital specialty portfolio, neuromuscular blockade medicine, Bridion injection generated sales of $449 million in the quarter, up 5%.